News Focus
News Focus
icon url

atheroprevent

09/14/09 8:56 AM

#28585 RE: haysaw #28584

Sorry about the lack of prescision in my posts. Nothing personal Haysaw. I did not intend to trigger last nights cascade.

Vynase is lisdexamfetamine itself is inactive and acts as a prodrug to dextroamphetamine, a well known devil to the FDA, that apparently will not lower the bar for ampakine entry into ADHD.

I still think that drugs are safer than ever. Unfortunately that perception is not widely shared. Most of my patients do not think "baby" Aspirin is a drug, hence take it freely on their own. They balk at taking a statin. The consequence in the past decade is trivial transient side effects from statin use vs life threatening bleeding requiring hospitalization in three of my patients with low dose aspirin. The FDA tolerates aspirin induced bleeding, approved the step up to plavix, but almost closed the door on the more effective Effient. The increment in bleeding risk is that of aspirin compared to placebo.
icon url

neuroinv

09/14/09 9:29 AM

#28586 RE: haysaw #28584

OK. I was confused because they were already well past IND stage with CX-717, having run their Phase I and Phase IIa studies. But you were referring to the amount potentially receivable had Laughren lifted the clinical hold on CX-717. Not an important point, I just wanted to make sure you weren't referring to the next actual 'approval' stage, NDA approval.

NeuroInvestment